Gross margin at 66.0% is exceptional for a company with significant hardware manufacturing. Unlike pure software, ISRG manufactures complex robotic systems, instruments, and accessories — making this margin a testament to pricing power. The filing notes instruments and accessories are replenished regularly as 'orders received are typically shipped within one business day,' confirming the consumable revenue stream's reliability.

OCF of $3.0B is 1.03x net income of $2.9B — a healthy ratio confirming reported earnings are backed by real cash. Unlike many medtech peers that rely on aggressive revenue recognition, ISRG's consumables-driven model generates cash as procedures are performed. The tight OCF/NI alignment reflects minimal accounting noise.

FCF of $2.5B represents a 24.8% FCF margin, with $0.5B in CapEx reflecting ongoing manufacturing investment at facilities in Sunnyvale, Peachtree Corners, Mexicali, and the Joint Venture in Shanghai. FCF is 86% of net income — the slight haircut from CapEx is appropriate for a company investing in global manufacturing scale.

Revenue reached $10.1B with domestic revenue at 68% and international at 32%. The filing notes 'domestic revenue accounted for 68%, 67%, and 66%, respectively, of total revenue' over FY2025-2023, showing gradual international mix shift. Seasonal patterns favor Q4 system placements as 'hospital budgets are reset' in Q1, creating predictable cadence.

ROE at 16.0% is solid though optically modest — this reflects ISRG's conservative, debt-light balance sheet rather than weak profitability. With virtually no financial leverage and 1.8% goodwill/assets, the 16% return is earned on genuinely organic equity, making it far more sustainable than leveraged peers showing 40%+ ROEs.

Goodwill at just 1.8% of total assets is a powerful signal: ISRG built its market dominance organically through R&D and clinical adoption, not through acquisitions. This is the hallmark of a genuine innovator — virtually all balance sheet value represents real assets and internally developed technology. No impairment risk exists.

The filing describes extensive training infrastructure: 'capital sales activities include educating surgeons or physicians and hospital staff across multiple specialties on the benefits of robotic-assisted surgery.' The clinical sales team 'works on site at hospitals, interacting with surgeons or physicians, operating room staff, and hospital administrators to develop and sustain successful robotic-assisted surgery programs.' Once trained on da Vinci, surgeons face enormous switching costs.

The installed base model creates compounding economics: each system placement generates years of recurring instrument, accessory, and service revenue. The filing states 'new direct customers who purchase a system typically place an initial stocking order of instruments and accessories soon after they receive their system,' with regular replenishment thereafter. The clinical sales team 'has grown with the expanded installed bases,' confirming the flywheel effect.

FCF margin of 24.8% ($2.5B/$10.1B) is strong for a hardware manufacturer. The gap between OCF margin (~29.7%) and FCF margin reflects disciplined CapEx investment in manufacturing facilities across Sunnyvale, Peachtree Corners, Mexicali, Shanghai, Blacksburg, Bulgaria, and Germany — a global footprint that supports long-term scale.

FCF at 86% of net income is reasonable given ongoing manufacturing expansion. The 14% gap represents growth CapEx — investment in new production lines and geographic manufacturing diversification. For a company scaling from $10.1B to what should be significantly higher revenue, reinvestment at this level is value-creating.

Near-zero goodwill confirms management's organic growth discipline. Unlike medtech peers who grow through serial acquisitions (often at 20-40% goodwill/assets), ISRG has invested in internal R&D to develop da Vinci, Ion endoluminal, and related platforms. This is Buffett's preferred capital allocation approach — growing through reinvestment rather than acquisition.

With 1.8% goodwill/assets and conservative leverage, ISRG maintains a fortress balance sheet. The Joint Venture in Shanghai demonstrates strategic capital deployment for China market access while managing geopolitical risk through a partnership structure rather than full ownership.

The filing describes clear seasonal patterns: 'placements of our da Vinci surgical systems have tended to be heavier in the fourth quarter and lighter in the first quarter' with 'lower procedure volume in the first and third quarters.' While this creates quarterly variability, the pattern is well-understood and predictable — more a planning factor than a risk.